Abstract
Natriuretic peptides are a family of peptides with similar structures, but are genetically distinct with diverse actions in cardiovascular, renal and fluid homeostasis. The family consists of an atrial natriuretic peptide (ANP) and a brain natriuretic peptide (BNP) of myocardial cell origin, a C-type natriuretic peptide (CNP) of endothelial origin, and a urodilatin (Uro) which is processed from a prohormone ANP in the kidney. Nesiritide, a human recombinant BNP, was approved by the Federal Drug Administration (FDA) for the management of acute heart failure (AHF) in 2001. Human recombinant ANP (Carperitide) was approved for the same clinical indication in Japan in 1995, and human recombinant Urodilatin (Ularitide) is currently undergoing phase III clinical trial (TRUE AHF). This review will provide an update on important issues regarding the role of BNP in fluid hemostasis as a biomarker and therapeutics in AHF.
| Original language | English (US) |
|---|---|
| Journal | Revista Clinica Espanola |
| DOIs | |
| State | Accepted/In press - Jan 11 2016 |
Fingerprint
Keywords
- Brain natriuretic peptide
- Heart failure
- Natriuretic peptide
- Recombinant natriuretic peptides
- Volume homeostasis
ASJC Scopus subject areas
- Medicine(all)
Cite this
B-type natriuretic peptide and acute heart failure : Fluid homeostasis, biomarker and therapeutics. / Torres-Courchoud, I.; Chen, Horng Haur.
In: Revista Clinica Espanola, 11.01.2016.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - B-type natriuretic peptide and acute heart failure
T2 - Fluid homeostasis, biomarker and therapeutics
AU - Torres-Courchoud, I.
AU - Chen, Horng Haur
PY - 2016/1/11
Y1 - 2016/1/11
N2 - Natriuretic peptides are a family of peptides with similar structures, but are genetically distinct with diverse actions in cardiovascular, renal and fluid homeostasis. The family consists of an atrial natriuretic peptide (ANP) and a brain natriuretic peptide (BNP) of myocardial cell origin, a C-type natriuretic peptide (CNP) of endothelial origin, and a urodilatin (Uro) which is processed from a prohormone ANP in the kidney. Nesiritide, a human recombinant BNP, was approved by the Federal Drug Administration (FDA) for the management of acute heart failure (AHF) in 2001. Human recombinant ANP (Carperitide) was approved for the same clinical indication in Japan in 1995, and human recombinant Urodilatin (Ularitide) is currently undergoing phase III clinical trial (TRUE AHF). This review will provide an update on important issues regarding the role of BNP in fluid hemostasis as a biomarker and therapeutics in AHF.
AB - Natriuretic peptides are a family of peptides with similar structures, but are genetically distinct with diverse actions in cardiovascular, renal and fluid homeostasis. The family consists of an atrial natriuretic peptide (ANP) and a brain natriuretic peptide (BNP) of myocardial cell origin, a C-type natriuretic peptide (CNP) of endothelial origin, and a urodilatin (Uro) which is processed from a prohormone ANP in the kidney. Nesiritide, a human recombinant BNP, was approved by the Federal Drug Administration (FDA) for the management of acute heart failure (AHF) in 2001. Human recombinant ANP (Carperitide) was approved for the same clinical indication in Japan in 1995, and human recombinant Urodilatin (Ularitide) is currently undergoing phase III clinical trial (TRUE AHF). This review will provide an update on important issues regarding the role of BNP in fluid hemostasis as a biomarker and therapeutics in AHF.
KW - Brain natriuretic peptide
KW - Heart failure
KW - Natriuretic peptide
KW - Recombinant natriuretic peptides
KW - Volume homeostasis
UR - http://www.scopus.com/inward/record.url?scp=84959511118&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959511118&partnerID=8YFLogxK
U2 - 10.1016/j.rce.2016.01.009
DO - 10.1016/j.rce.2016.01.009
M3 - Article
AN - SCOPUS:84959511118
JO - Revista Clinica Espanola
JF - Revista Clinica Espanola
SN - 0014-2565
ER -